Navigation Links
Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
Date:10/15/2007

- Data Presented at the American College of Gastroenterology Annual

Scientific Meeting -

PHILADELPHIA, Oct. 15 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that data from the first cohort of patients from an exploratory Phase 2 study evaluating the efficacy and safety of AST-120 in patients with active pouchitis was presented in a poster presentation at the American College of Gastroenterology Annual Scientific Meeting.

"A four-week treatment with AST-120 in patients with active pouchitis led to a significant decrease in symptoms of pouchitis and endoscopy scores in the first ten patients enrolled in the study," said Dr. Bo Shen, principal investigator at the Center for Inflammatory Bowel Disease, Cleveland Clinic. "These results were impressive with 44.4% of the patients achieving clinical remission and 55.6% achieving a clinical response."

"These promising results warrant the further evaluation of AST-120 for the treatment of pouchitis in controlled randomized studies," added Laurent Fischer, M.D. president and CEO of Ocera Therapeutics. "We are encouraged by these findings which further support our strategy of exploring AST-120 as a platform drug with the potential to address multiple gastrointestinal and liver diseases."

Patients who suffer from Ulcerative Colitis often require a resection of the colon to reduce the risk of cancer. A J-pouch is created to collect stools and the pouch often becomes inflamed, a condition known as pouchitis, which is associated with diarrhea, abdominal cramps, fever and dehydration. Pouchitis occurs in up to 40% of patients with a J-pouch and there are no treatments currently approved for this indication. An estimated 80,000 patients in the United States suffer from this condition, which qualifies a
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... 16, 2014  Vermillion, Inc. (NASDAQ: VRML ... today announced the next step in its expanded strategy ... provider with the naming of current Chief Operating Officer, ... Officer, while current Chairman of the Board and CEO ... Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... -- Good computer security requires careful attention not just to ... to Debbie Christofferson, president of Sapphire Security Services . ... it open a crack, or are all your windows open? ... conference in Milwaukee . , ,Referring to the title of ...
... MADISON - Some of the first data from a new ... and by analogy galaxies in general - is making new ... , ,The findings from NASA's Spitzer Space Telescope were announced ... Edward Churchwell, a University of Wisconsin-Madison astronomer and the leader ...
... Sonic Foundry s Mediasite have a home ... help organizations capture presentations digitally and publish them on the ... for Mediasite, the companies announced in statements released in tandem ... can leverage the power of rich media communications without the ...
Cached Biology Technology:Expert says network security is about people, not just computers 2Milky Way churning out new stars at a furious pace 2Milky Way churning out new stars at a furious pace 3BxVideo designs Web hosting service for Sonic Foundry media presentations 2
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... DETROIT Diabetes Mellitus (DM), a metabolic disorder that ... chronic hyperglycemia that disrupts carbohydrate fat and protein metabolism ... both. DM can cause long-term damage, dysfunction and even ... may develop corneal complications and delayed wound healing. This ...
... Nuclear Magnetic Resonance (NMR) Spectroscopy is an extremely powerful ... by chemists from its origin, it is now essential ... scope extended in biological laboratories. Coupled with NMR, ... the enhancement of NMR signals from a wide range ...
... to five protective antigens, the presence of which are critical to ... been present in almost all isolates of Bordetella pertussis ... more than half of them, according to a paper published ahead ... "These findings tell us that there is an evolutionary advantage to ...
Cached Biology News:Wayne State discovers potential treatment for skin and corneal wound healing in diabetics 2A powder to enhance NMR signals 2Whooping cough vaccine antigen disappearing from bacteria in US 2
...
... contains the basic components required for the ... and recombinant rat Thymus Chemokine-1 in cell ... sufficient materials to run ELISAs on approximately ... conditions are met: The assay ...
Blimp-1 (H-150)...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: